HOMAPIN-10
Clinical safety rating: caution
Comprehensive clinical and safety monograph for HOMAPIN-10 (HOMAPIN-10).
Homapin-10 is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, leading to decreased peripheral vascular resistance and blood pressure.
| Metabolism | Hepatic metabolism via CYP2D6 and CYP3A4; undergoes glucuronidation. |
| Excretion | HOMAPIN-10 is primarily excreted renally as unchanged drug (70-80%), with biliary/fecal elimination accounting for 15-20% and minor metabolism 5-10%. |
| Half-life | Terminal elimination half-life is 3-5 hours in adults with normal renal function; prolonged in renal impairment (up to 20 hours in severe cases), necessitating dose adjustment. |
| Protein binding | 45-55% bound primarily to albumin; lower binding in hypoalbuminemia. |
| Volume of Distribution | 1.2-1.5 L/kg, indicating extensive distribution into tissues, with high concentrations in lungs, kidney, and liver. |
| Bioavailability | Oral: 70-85% (first-pass metabolism minimal); Intramuscular: 90-100%. |
| Onset of Action | Oral: 30-60 minutes; Intramuscular: 15-30 minutes; Intravenous: 5-15 minutes. |
| Duration of Action | Oral: 4-6 hours; Parenteral: 3-5 hours; clinical effects persist longer in hepatic or renal impairment. |
| Molecular Weight | 358.5 |
10 mg orally every 8 hours as needed for extrapyramidal symptoms; maximum 30 mg per day.
| Dosage form | TABLET |
| Renal impairment | No adjustment needed for mild to moderate impairment (GFR >30 mL/min). For severe impairment (GFR <30 mL/min), reduce dose by 50% and monitor. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use. |
| Pediatric use | For children >3 years: 0.5-2 mg orally every 8 hours as needed; maximum 6 mg/day for weight <20 kg, maximum 12 mg/day for weight 20-40 kg. |
| Geriatric use | Initiate at 5 mg orally every 8 hours; titrate slowly; monitor for anticholinergic effects and confusion. |
| 1st trimester | Avoid due to potential anticholinergic effects and lack of safety data. |
| 2nd trimester | Use only if clearly needed; limited data suggest possible risks. |
| 3rd trimester | May cause neonatal anticholinergic effects; avoid near term. |
Clinical note
Comprehensive clinical and safety monograph for HOMAPIN-10 (HOMAPIN-10).
| Placental transfer | Likely crosses placenta based on molecular weight (<500 Da) and lipophilicity. |
| Breastfeeding | Excretion into breast milk is unknown; however, due to low molecular weight, it may be present. Use with caution, especially in neonates. |
| Lactation Rating |
■ FDA Black Box Warning
None
| Serious Effects |
Narrow-angle glaucomaTachycardiaMyasthenia gravisSevere ulcerative colitisToxic megacolon
| Precautions | May cause sedation and dizziness; avoid abrupt discontinuation to prevent rebound hypertension; use with caution in patients with hepatic impairment, history of depression, or bradycardia. |
| Food/Dietary | Avoid alcohol as it may enhance CNS depression (minimal with this drug but caution). High-fiber foods or large meals may delay absorption; take before meals as directed. No specific food restrictions, but maintain adequate hydration to minimize constipation. |
| Clinical Pearls |
Loading safety data…
| L3 (Moderately Safe) |
| Teratogenic Risk | HOMAPIN-10 (homatropine methylbromide) is an anticholinergic agent. FDA pregnancy category C: animal studies have shown adverse effects on the fetus (increased resorptions, delayed ossification) at maternally toxic doses. No adequate human studies. First trimester: limited data suggest no major malformations; however, anticholinergics may be associated with minor anomalies. Second and third trimesters: may cause fetal tachycardia, reduced gastrointestinal motility, and meconium ileus. Avoid if possible; use only if clearly needed. |
| Fetal Monitoring | Monitor maternal heart rate and blood pressure due to potential anticholinergic side effects (tachycardia, hypertension). Assess for anticholinergic symptoms (blurred vision, urinary retention, constipation). In the fetus/neonate, monitor heart rate for tachycardia and gastrointestinal function for delayed meconium passage. |
| Fertility Effects | Homatropine methylbromide may impair male and female fertility by reducing libido and causing erectile dysfunction or anorgasmia due to anticholinergic effects on autonomic nervous system. Reversible upon discontinuation. No specific data on fertility in humans; animal studies show no direct reproductive toxicity at therapeutic doses. |
| HOMAPIN-10 (homatropine methylbromide 10 mg) is a quaternary ammonium anticholinergic with poor CNS penetration, thus fewer central side effects like sedation or confusion compared to tertiary amines. It is primarily used for GI hypermotility disorders. Onset is 30-60 minutes; duration 4-6 hours. Contraindicated in glaucoma, myasthenia gravis, obstructive uropathy, and GI obstruction. Monitor for anticholinergic toxicity (tachycardia, dry skin, dilated pupils, urinary retention). Use caution in elderly due to fall risk from blurred vision and orthostasis. |
| Patient Advice | Avoid driving or operating machinery if you experience blurred vision or dizziness. · Do not take with other anticholinergic medications (e.g., antihistamines, tricyclic antidepressants) without doctor approval. · Report any eye pain, difficulty urinating, or rapid heartbeat to your healthcare provider immediately. · Take on an empty stomach 30-60 minutes before meals for optimal GI motility suppression. · Do not crush or chew tablets; swallow whole. |